This past Wednesday, the results of a phase
The FDA, however, is holding CellCept to an extremely high standard of surpassing a similar drug – intravenous Cyclophosphamide (
The Lupus Foundation of America is eager to see a subset analysis, and hopes the FDA will take into account the findings of such an analysis. Once that analysis is complete, it could be found that CellCept is associated with fewer serious or life-threatening infections, and hospitalizations (which plague
The results released Wednesday are only preliminary. We at the LFA look forward to further analysis of the data and will report this information as soon as it becomes available.